$ Value
$8.4M
Shares
304,684
Price
$28
Filed
Apr 1
Insider
Name
Gline Matthew
Title
CEO
CIK
0001750094
Roles
Transaction Details
Transaction Date
2026-03-31
Code
F
Table
Non-Derivative
Ownership
Direct
Equity Swap
No
Shares After
17,025,890
Footnotes
Reflects the conversion of capped value appreciation rights ("CVARs") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the applicable hurdle price reflected in column 8 of Table II above (such excess, the "CVAR Amount"). | On March 30, 2026, the hurdle price applicable to 2,178,150 vested CVARs was satisfied and, accordingly, the CVARs were settled into 97,319 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on March 30, 2026. | Represents the "net settlement" by the Issuer of CVARs in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such CVARs. | Represents the "net settlement" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs. | Award of CVARs is fully vested.
Filing Info
Gline Matthew's History
| Date | Ticker | Type | Value |
|---|---|---|---|
| 2026-04-16 | ROIV | ▼ | $8.4M |
| 2026-03-31 | ROIV | F | $8.4M |
| 2026-03-30 | ROIV | M | — |
| 2026-03-30 | ROIV | F | $1.4M |
| 2026-03-30 | ROIV | M | $25.0M |
| 2025-05-20 | ROIV | F | $121K |
Other Insiders at ROIV (90d)
| Insider | Bought | Sold | Last |
|---|---|---|---|
| MOMTAZEE JAMES C | — | — | 2026-04-17 |
| Fitzgerald Meghan | — | $1.9M | 2026-03-26 |
| Oren Ilan | — | — | 2026-04-17 |
|
Torti Frank
President and Vant Chair
|
— | — | 2026-03-31 |
|
Sukhatme Mayukh
President & CIO
|
— | — | 2026-03-31 |
|
Gline Matthew
CEO
|
— | $8.4M | 2026-04-16 |
|
Venker Eric
President & Immunovant CEO
|
— | $5.9M | 2026-04-20 |
| Epperly Melissa B, | — | — | 2026-04-17 |
|
Pulik Richard
CFO
|
— | — | 2026-04-20 |
|
Humes Jennifer
Chief Accounting Officer
|
— | $384K | 2026-04-20 |